First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Can't or Refuse Receive Conditioning Regimen Followed by Autograft
Demonstration of Improvement of progression-free survival (PFS) compared to literature data.
6 months prolongation equal 24 months compared to 18 months obtained whatever the current
regimen and in particular compared to RCHOP regimen
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Improvement of progression-free survival (PFS)
Improvement of progression-free survival (PFS) compared to litterature data 6 months prolongation 24 months compared to 18 months obtained whatever the current regimen and in particular compared to RCHOP regimen in reference with Lenz JCO 2005
18 months
Yes
Rémy GRESSIN, MD
Principal Investigator
Groupe Est Ouest des Leucémies et autres Maladies du Sand
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Manteau RiBVD
NCT01457144
October 2011
April 2018
Name | Location |
---|